Waltz dances into direct-to-employer sales of obesity drugs

With direct-to-consumer (DTC) sales of weight-loss therapies in the headlines almost every week, Waltz Health has entered the market with a new model – targeting employers.

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), according to the company, and is designed to give self-insured employers “a new pathway to deliver coverage for these medicines.”

Chicago-based Waltz Health, which was bought by pharmaphorum parent EVERSANA in August for an undisclosed sum, is a digital…